BioSpace News Archive

Predictive Oncology Inc., a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, announced the closing of its previously announced registered direct offering of 3,414,970 shares of its common stock, at a purchase price of $1.20 per share, which was priced at-the-market under Nasdaq rules.

Personalis, Inc., a leader in advanced genomics for population sequencing and cancer, announced the pricing of its previously announced underwritten public offering of 3,950,000 shares of its common stock at a price to the public of $38.00 per share.

Casio Computer Co., Ltd. announced the upcoming release of the DZ-D100 DERMOCAMERA that allows close-up shots with the lens directly touching the skin as well as ordinary shots, all using a single camera.

Brewer Is a 35-Year Consumer and Retail Industry Veteran with Deep Experience in Transformational, Operational and Digital Strategies

Scopus BioPharma Inc. announced the pricing of a $9 million follow-on public offering. The offering consists of 1,000,000 shares of common stock at a public offering price of $9.00 per share.

TransEnterix, Inc. announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 23,083,333 shares of common stock of the Company at a public offering price of $3.00 per share, less underwriting discounts and commissions.

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of its previously announced privately negotiated exchange transactions (the “Exchange Transactions”) with certain holders of its 3.500% Convertible Senior Notes due 2026 issued in September 2019

TransEnterix, Inc. (NYSE American: TRXC) (“TransEnterix” or the “Company”), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co.

Today, Biosenta realized its first purchase order and payment from the supply and purchase agreement with SANITIZATION 360.

Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company’s track record as a premiere CDO service provider in the global market.